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TO THE EDITOR
We have previously performed a micro-
array analysis of expressed genes in
purified epidermal cells from lesional
skin of psoriasis and atopic dermatitis
(AD) patients (de Jongh et al., 2005).
The complete data set revealed more
than 180 genes that showed signi-
ficantly different expression between
the two diseases. The observed generali-
zed overexpression of host defense
genes in psoriasis was studied in depth
at the protein and cellular level (de
Jongh et al., 2005). Among the genes
that were found to be upregulated in
AD skin, carbonic anhydrase II (CA II,
HUGO gene symbol: CA2) was upre-
gulated eightfold (Po105). Similar
upregulation of CA II was previously
identified independently using micro-
array analysis of full-thickness skin
biopsies (Nomura et al., 2003). No
validation at the mRNA or protein level
was provided by any of these micro-
array studies. CA II belongs to the
family of metalloenzymes that catalyze
the reversible reaction: CO2þH2O3
HCO3
þHþ (Geers and Gros, 2000;
Boron, 2004). Fourteen different iso-
forms are known so far and they all
show distinct distribution patterns (Sly
and Hu, 1995; Mastrolorenzo et al.,
2003). CA II is broadly expressed in a
variety of tissues, including kidney,
erythrocytes, sweat glands, salivary
glands, and skin (Spicer et al., 1982;
Briggman et al., 1983; Noda et al.,
1986; Mastrolorenzo et al., 2003) and
the enzyme is involved in the main-
tenance of cellular pH, water transport,
and ion homeostasis. The importance of
CAs in these processes is witnessed by
the pharmacological inhibition of these
enzymes to reduce intraocular fluid
pressure in glaucoma patients (Casini
et al., 2000). Firstly, the aim of this
study was to validate these preliminary
microarray data on CA II at the mRNA
and protein level and secondly to
examine the cellular source and regula-
tion of CA II gene expression. We
therefore examined lesional epidermis
of psoriasis and AD patients. Quantifi-
cation of CA II mRNA by real time PCR
(qPCR) revealed an increase in CA II
expression in epidermal sheets of le-
sional skin of AD patients compared
with lesional skin of psoriasis patients
and healthy controls (Figure 1a), there-
by confirming the microarray data. CA
II expression in lesional psoriatic epi-
dermis is significantly lower than in
normal skin. Statistical analysis of the
data depicted in Figures 1a, c, and 2b
was performed by analysis of variance
followed by a Duncan’s multiple range
post hoc test. To examine whether the
changes in CA II mRNA result in
changes at the protein level, a second
cohort of patients and healthy indivi-
duals, which was different from the first
study, was analyzed by Western blot-
ting (rabbit CA II antibody; Abcam,
Cambridge, UK) and ELISA (rabbit CA
II-capturing antibody and a sheep CA II
antibody; R&D Systems, Minneapolis,
MN). AD patients (extrinsic type, mean
age 52 years) were from our in-patient
department and had moderate to severe
AD, according to the Hanifin criteria.
Patients suffered from chronic AD, but
were in an active phase of disease, for
which they were hospitalized and the
lesions were regarded as (sub)acute
lesions. Biopsies were taken from le-
sional skin, but care was taken to
exclude vesicles or scratched skin. All
psoriasis patients (mean age 60 years)
had moderate to severe plaque type
psoriasis. Patients were all diagnosed
by a dermatologist; the study was
approved by the local medical ethical
committee and adhered to the Declara-
tion of Helsinki Principles. Written
informed consent was obtained. BothAbbreviations: CA, carbonic anhydrase; AP, atopic dermatitis
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Western blot analysis and ELISA
showed that CA II protein expression
in epidermis of AD was higher than in
normal skin and psoriasis (Figure 1b
and c). To analyze if CA II expression
was stratum-specific, basal and differ-
entiated keratinocytes from normal skin
biopsies were sorted by flow cytometry
on the basis of b1-integrin expression
(Franssen et al., 2005). CA II mRNA
levels were measured by qPCR and
revealed that CA II is almost exclusively
expressed in the differentiated keratino-
cytes (data not shown). Immunohisto-
chemistry confirmed the expression in
the suprabasal keratinocytes of both
normal and diseased skin. Figure 1d
shows the cytoplasmic localization in
suprabasal cells of AD skin as an
example.
AD is characterized by a Th2-
mediated immune response, whereas
in psoriasis mainly Th1 cytokines are
present. To examine if these cytokines
influence CA II expression, or whether
cell-autonomous differences between
AD, psoriasis, and controls determine
the CA II expression level, confluent
keratinocytes cultured from healthy
volunteers and non-affected skin of
AD and psoriasis patients were exposed
to Th1 or Th2 cytokines. qPCR data
revealed that CA II mRNA was not
induced by Th1 cytokines in any of the
keratinocyte groups, whereas Th2 cyto-
kines increased CA II expression almost
fourfold in keratinocytes from AD and
psoriasis patients and from healthy
volunteers (Figure 2a). The observed
induction of CA II mRNA by Th2
cytokines also resulted in an increased
CA II protein level as revealed by
Western blot analysis (Figure 2b) and
ELISA (data not shown). Dose–response
experiments revealed that a plateau of
CA II expression is reached at a Th2
cytokine concentration of 10 ng/ml
(data not shown). At this concentration,
a maximum CA II mRNA level was
observed after 24 hours of stimulation,
whereas a maximum CA II protein level
was found after 48 hours (data not
shown).
Our findings suggest that relative
overexpression of CA II as initially
found by microarray analysis of AD
and psoriasis skin is probably due to
differences in cytokine environment.
These data indicate that there is no
cell-autonomous (genetically pro-
grammed) difference between these
groups with respect to CA II upregula-
tion. Although CA II is regarded as a
ubiquitously expressed enzyme, our
immunohistochemical data show that,
in skin, expression is particularly high
and inducible in keratinocytes, which
may be relevant for understanding
epidermal physiology and abnormali-
ties found in inflammatory skin disease.
Our findings are at variance with one
earlier study on CAs in human skin
(Mastrolorenzo et al., 2003), showing
CA II in the basolateral membrane of
the basal keratinocyte layer, which is
unexpected in view of the presumed
cytoplasmic localization of this enzyme
in other cells. We believe that our
results are correct, as we find supra-
basal expression at the mRNA and pro-
tein level, using various independent
techniques.
The (patho)physiological signifi-
cance of these findings remains to be
explored at the moment, but it is
tempting to link the differential expres-
sion (high in AD, low in psoriasis) to
differences in the clinical phenotype of
these diseases. The increased level of
CA II in AD epidermis could cause a
pathological cellular CA II activity in
selected keratinocytes that are exposed
to Th2 cytokines. CAs are involved in
the maintenance of cellular pH and
water homeostasis (Nakhoul et al.,
1998). In vitro studies have shown that
pharmacological inhibition of CA II
lowers the intracellular pH in a number
of cell types (Johanson et al., 1992;
Bonanno et al., 1995; Kniep et al.,
2006). Elevated skin surface pH values
have been reported in AD patients
(Eberlein-Konig et al., 2000), and re-
cently it was shown that alkalinization
of the stratum corneum leads to an
altered barrier function (Hachem et al.,
2003). Speculatively, increased expres-
sion of CA II in AD epidermis might
contribute to abnormalities in intracel-
lular and extracellular pH. Alterna-
tively, the CA II increase could be
a compensatory response to the ele-
vated pH as an attempt to restore
cellular pH. However, as CA II is
induced by Th2 cytokines, we interpret
increased CA II expression as an
early epidermal response to activated
Th2 T lymphocytes, and as such it
could contribute to other pathological
changes that are characteristic for AD,
such as spongiosis. It is of interest to
note that skin of AD patients is often
colonized with Staphylococcus aureus



















































Figure 1. CA II is upregulated in lesional skin of AD patients and is present in differentiated
keratinocytes. (a) CA II mRNA levels in epidermal sheets were significantly higher (Po0.0002) in lesional
skin from AD patients (n¼6) than in normal skin (NS) (n¼ 5), whereas it was significantly lower
(Po0.005) in lesional skin from psoriasis patients (PS) (n¼ 9). CA II mRNA levels were determined by
qPCR as described previously (Franssen et al., 2005). (b) Western blot analysis of epidermal sheets of four
individuals in each group showing similar findings for CA II protein levels as found at the mRNA level.
(c) Quantification of CA II protein levels in the same material using ELISA showed that in AD, CA II
protein was significantly higher than in NS (Po0.0005), whereas it was significantly lower in PS
(Po0.05). (d) CA II is predominantly expressed in the suprabasal keratinocytes as shown here by
immunostaining of lesional AD skin. Bar¼ 100mm.
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infections with S. aureus (Leung and
Bieber, 2003). As S. aureus prefers a
neutral pH, disturbance of skin-surface
pH may affect microbial colonization
and infection of the skin. Clearly, the
physiological consequences at the
cell and tissue level owing to increased
CA II expression require further inves-
tigation. Future studies will be directed
at the role of epidermal CA II in the
maintenance of intracellular pH and




Microarray data on gene expression levels in
lesional psorasis and AD epidermal cells
have been deposited, compliant with
MIAME criteria, at http://www.ncbi.nlm.
nih.gov/geo/ and are accessible through
GEO Series accession number GSE6601.
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Figure 2. CA II expression is induced by Th2 cytokines but not by Th1 cytokines. (a) No significant effect
of the diagnosis on CA II expression was found in cultured keratinocytes derived from seven healthy
donors (NS) and non-lesional skin of six AD patients and seven PS. Keratinocytes were cultured in
keratinocyte growth medium (KGM) and allowed to differentiate by growth factor depletion as described
before (Pfundt et al., 1996). Independent of the diagnosis, 48 hours stimulation by Th2 cytokines
(50 ng/ml IL-4 and 50 ng/ml IL-13; Peprotech, London, UK) significantly increased CA II mRNA levels
(Po0.0002) compared with untreated keratinocytes (KGM without growth factors), whereas 48 hours of
Th1 cytokine stimulation (30 ng/ml IL-1a (Peprotech), 30 ng/ml tumor necrosis factor-a (Peprotech) and
10 U/ml IFN-g (Hycult Biotechnology, Uden, The Netherlands)) had no effect on CA II expression levels.
CA II mRNA levels were determined as in Figure 1. (b) A Western blot representative for all these
keratinocyte cultures shows that CA II protein levels were also increased after 48 hours of Th2 cytokine
stimulation and not by 48 hours of Th1 cytokine stimulation. Purified CA II (Sigma-Aldrich, St Louis, MO)
was used as a positive control (þC).
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TO THE EDITOR
Psoriasis is characterized by keratino-
cyte proliferation, inflammation, and
mast cell activation (Schon and
Boehncke, 2005). It is also triggered or
exacerbated by acute stress (Katsarou-
Katsari et al., 1999; Saraceno et al.,
2006); however, this mechanism
remains poorly understood. Stress typi-
cally results in release of corticotropin-
releasing hormone (CRH) from the
hypothalamus and regulates the hy-
pothalamic–pituitary–adrenal (HPA)
axis (Chrousos, 1995) through activa-
tion of CRH receptor-1 (CRH-R1),
leading to immunosuppression. CRH is
also found peripherally (Chrousos,
1995) and has pro-inflammatory effects
through mast cell activation (Theohar-
ides et al., 1998). CRH and CRH-R gene
expression has been documented in
rodent and human skin (Slominski
et al., 2001). In fact, it has been
proposed that skin has the equivalent
of the HPA axis (Slominski et al., 2000).
In mice, CRH is released from nerve
endings (Slominski et al., 2001),
whereas in humans it is synthesized
by skin cells (Slominski et al., 1998),
immune cells (Karalis et al., 1997), and
human mast cells (Kempuraj et al.,
2004).
To study the effect of stress and the
role of CRH in psoriasis, we investi-
gated, by quantitative PCR, CRH-R
expression in affected and unaffected
skin of psoriasis patients (n¼13) and
skin from normal controls (n¼ 4), as
well as serum CRH levels from psoriasis
patients (n¼8) and controls (n¼4). The
characteristics of the subjects (Table S1)
were as follows: male mean age
47.477.0 years (n¼ 7); female mean
age 28.075.2 years (n¼ 6); normal
subjects (one male, three female sub-
jects, mean age 40715.2 years). All
skin biopsies requiring two stitches
were collected for diagnostic purposes
(Table S1). The Medical Ethics Commit-
tee of Attikon Hospital HIRB approved
this protocol. All participants gave their
written informed consent according to
the Declaration of Helsinki Principles.
Patients had moderate chronic plaque
psoriasis with psoriasis area and sever-
ity index (PASI) scores 5–16 and had
not received any therapy for psoriasis
(topical or systemic) for the past month.
The PASI score for males was
11.3713.5 and for females was
11.573.7.
Expression of CRH-R1 mRNA was
lowest in affected samples from psoriasis
patients (0.2770.23, n¼ 13, Po0.05),
compared with control patients (Figure
1a). CRH-R1 expression in unaffected
skin from psoriasis patients (0.5370.38)
was not statistically different from that of
affected samples or controls (Figure 1a).
There was no statistically significant
difference in CRH-R2 mRNA expression
among the control samples, those ob-
tained from affected (0.8670.51) and
from unaffected (0.9770.65) psoriatic
skin (Figure 1a).
The serum CRH level (11.527
6.09 pg/ml) was higher (n¼8, Po0.05)
in psoriasis patients than controls
(5.4271.2 pg/ml, n¼ 8). There was no
apparent correlation between the PASI
scores and either CRH-R1 expression or
serum CRH levels.
This study provides early evidence
that affected psoriatic skin has decreased
gene expression of CRH-R1 mRNA than
normal controls. One possible explana-
tion is that overstimulation by increased
levels of local or systemic (serum) CRH
in psoriasis patients, possibly in response
to chronic stress, may lead to CRH-R1
downregulation. In fact, CRH protein
expression was recently reported to be
increased in the affected skin of three
patients with active psoriasis than in one
control; however, this effect was not
quantitated (O’Kane et al., 2006). As
non-affected psoriatic skin apparently
did not overexpress CRH-R, as shown
by our quantitative real-time–PCR data,
there was apparently no mechanism in
place to lead to downregulation. In-
creased CRH-R expression in psoriatic
skin was also mentioned as ‘‘unpub-
lished observations’’ (O’Kane et al.,
2006) and it is, therefore, difficult to
evaluate it. The reduction in CRH-R1
mRNA expression in affected skin of
patients with psoriasis we observed
could be due to the intense inflamma-
tion seen in plaques without any asso-
ciation with serum CRH levels; how-
Abbreviations: CRH, corticotropin-releasing hormone; HPA, hypothalamic–pituitary–adrenal; CRH-R1,
CRH receptor-1; PASI, psoriasis area and severity index
www.jidonline.org 1789
M Tagen et al.
Skin CRH Receptors in Psoriasis
